查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1987390

基因检测市场规模、份额、趋势和预测：按类型、技术、应用和地区划分，2026-2034年

Genetic Testing Market Size, Share, Trends and Forecast by Type, Technology, Application, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

2025年全球基因检测市场规模为214亿美元。展望未来，IMARC集团预测，该市场将在2026年至2034年间以8.93%的复合年增长率成长，到2034年达到473亿美元。目前，北美市场占据主导地位，预计2025年市占率将超过45.6%。北美市场成长的主要驱动因素包括技术进步、对个人化医疗日益增长的需求、遗传疾病盛行率上升、政府扶持政策的出台以及伦理、法律和社会因素日益受到重视。

目前，各类遗传性疾病在一般人群中的发生率不断上升。囊肿纤维化、镰状细胞贫血和亨丁顿舞蹈症等具有显着遗传因素的疾病，在研究和临床应用中都备受关注。此外，癌症和心血管疾病等慢性疾病发生率的上升（这些疾病通常与遗传易感性相关）进一步凸显了透过基因检测进行早期诊断的必要性。由于早期识别这些疾病能够显着改善患者的预后，基因检测已成为预防医学中不可或缺的工具。基因组学的进步使得基于个体基因谱的个人化治疗方案成为可能，从而带来疗效更佳、副作用更少的治疗方法。医生和医疗保健专业人员越来越多地利用基因检测来指南癌症治疗、罕见疾病管理和慢性病干预等方面的决策。

由于精准医疗的进步，美国正崛起为基因检测市场的重要区域。医疗专业人员越来越依赖基因检测来指南医疗决策，尤其是在肿瘤学、循环系统和罕见疾病领域。这些检测透过识别基因突变和多态性，帮助临床医生预测疾病风险、评估疾病进展并提供个人化治疗。在美国，基因检测是生殖医学的重要组成部分。带因者筛检和非侵入性产前检测（NIPT）在希望分析自体遗传疾病风险的孕妇中越来越普遍。 NIPT尤其被广泛应用，因为它可以透过血液检测发现唐氏症等染色体异常。这项技术减少了羊膜穿刺等高风险侵入性手术的需求。生育诊所和产科诊所基因检测的日益普及，反映了将基因组学融入计划生育和产前护理的更广泛趋势。根据 IMARC 集团的预测，到 2033 年，美国基因检测市场预计将达到 144 亿美元。

基因检测市场的发展趋势：

基因检测技术的进步

基因检测技术的进步是基因检测市场的关键驱动力。这些创新使得基因分析方法更加精准、高效且经济，并将检测范围扩展至肿瘤学、药物基因体学和预测性检测等领域，进一步推动市场成长。先进的定序技术，例如次世代定序（NGS），能够提供关于遗传疾病的详细信息，从而实现早期检测和个性化治疗方案的发展。例如，一项针对1914名女性的研究表明，与标准筛检方面达到了100%的成功率，并展现出更高的预测价值。此外，流程的简化正在加速基因检测在各种医疗机构中的应用，从而推动基因检测市场的需求成长。

人们对个人化医疗的认识和需求日​​益增长

人们对个人化医疗的日益关注和需求正在显着影响基因检测市场的格局。个人化医疗基于基因资讯优化治疗方法，推动了基因检测的需求。这种需求在肿瘤学和生殖医学等领域尤其明显，基因检测能够引导治疗决策并评估后代罹患遗传性疾病的风险。例如，一项研究显示，在36%的回覆率下，312名受访者中有83%至少对面向消费者的基因检测进行初步了解。此外，14%的受访者参与了结果解读，超过50%的受访者支持遗传咨询师和临床实践在基因检测中的作用，70%的受访者表示愿意考虑为那些对隐私、匿名或获取途径有所顾虑的患者提供基因检测。此外，人们对了解遗传易感性与健康状况之间关係的兴趣日益浓厚，也进一步促进了市场成长。

遗传性疾病和慢性病增多

全球遗传性疾病和慢性病的增加进一步推动了基因检测市场的发展。基因检测在镰状细胞贫血症、囊肿纤维化和亨廷顿舞蹈症等多种疾病的早期发现、诊断和管理中发挥着至关重要的作用。此外，随着癌症、心血管疾病和糖尿病等慢性病发病率的上升，对识别导致个体患有这些疾病的基因突变的检测需求也日益增长。世界卫生组织（WHO）的数据显示，癌症、心血管疾病和糖尿病等非传染性疾病（NCDs）占全球每年死亡人数的73%。基因检测有助于识别这些疾病的高风险族群。透过检测进行早期发现可以改善患者的预后，从而进一步推动市场扩张。基因检测市场规模庞大，美国和其他已开发国家的年检测率显着成长。孕期基因检测也越来越普遍，为胎儿健康和遗传疾病提供了宝贵的资讯。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 调查方法

第三章执行摘要

第四章：引言

第五章：全球基因检测市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依类型

  • 预测性和无症状检测
  • 基因带原检测
  • 产前和新生儿筛检
  • 诊断测试
  • 药物基因体学学检测
  • 其他的

第七章 市场区隔：依技术划分

  • 细胞遗传学检测和染色体分析
  • 生物化学检验
  • 分子检测
    • 主要部分
      • DNA定序
      • 其他的

第八章 市场区隔：依应用领域划分

  • 癌症诊断
  • 遗传疾病的诊断
  • 心血管疾病的诊断
  • 其他的

第九章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十章 SWOT 分析

第十一章：价值链分析

第十二章：波特五力分析

第十三章：价格分析

第十四章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • 23andme Inc.
    • Ambry Genetics Corporation（Konica Minolta Healthcare Americas Inc.）
    • Bio-RAD Laboratories Inc.
    • Cepheid（Danaher Corporation）
    • Eurofins Scientific
    • Illumina Inc.
    • Invitae Corporation
    • Luminex Corporation（DiaSorin）
    • Myriad Genetics Inc.
    • QIAGEN
    • Quest Diagnostics
    • Thermo Fisher Scientific
Product Code: SR112026A5788

The global genetic testing market size was valued at USD 21.4 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 47.3 Billion by 2034, exhibiting a CAGR of 8.93% from 2026-2034. North America currently dominates the market, holding a market share of over 45.6% in 2025. The North American market is primarily driven by technological advancements, escalating demand for personalized medicine, rising prevalence of genetic disorders, introduction of supportive government initiatives, and increasing implication of ethical, legal, and social considerations.

At present, there is a rise in the occurrence of various genetic disorders among the masses. Conditions such as cystic fibrosis, sickle cell anemia, and Huntington's disease, which have strong genetic components, are receiving more attention in both research and clinical applications. Additionally, the increasing incidence of chronic conditions like cancer and cardiovascular diseases, often linked to genetic predisposition, has further underscored the need for early diagnosis through genetic testing. Early identification of such conditions can significantly improve patient outcomes, making genetic testing an essential tool in preventive healthcare. Advances in genomics are enabling tailored treatment options based on an individual's genetic profile, leading to better therapies with fewer side effects. Physicians and healthcare providers are increasingly adopting genetic testing to guide decisions for cancer treatment, rare disease management, and even chronic condition interventions.

The United States has emerged as a significant region in the genetic testing market owing to the advances in precision medicine. Healthcare providers are increasingly relying on genetic tests to guide medical decision-making, especially for oncology, cardiology, and rare diseases. By identifying genetic mutations or variations, these tests help clinicians predict disease risks, determine disease progression, and tailor treatments to the individual. Genetic testing has become a critical component of reproductive health in the United States. Carrier screening and non-invasive prenatal testing (NIPT) are increasingly common among expectant parents who want to analyze the risk of passing genetic issues to children. NIPT, in particular, has gained widespread adoption due to its ability to detect chromosomal abnormalities like Down syndrome, via a blood test. This technology has reduced the need for invasive procedures like amniocentesis, which carry higher risks. The growing use of genetic testing in fertility clinics and obstetric practices reflects a broader trend of integrating genomics into family planning and prenatal care. As per the IMARC Group's predictions, the US genetic testing market is expected to reach USD 14.4 billion by 2033.

GENETIC TESTING MARKET TRENDS:

ADVANCEMENTS IN GENETIC TESTING TECHNOLOGIES

Advancements in genetic testing technologies are instrumental in driving the genetic testing market. These technological innovations have led to more accurate, efficient, and cost-effective genetic analysis methods, expanding the scope of testing into areas such as oncology, pharmacogenomics, and predictive testing, further supporting the market growth. Enhanced sequencing techniques, such as next-generation sequencing (NGS) , provide detailed insights into genetic disorders, enabling early detection and personalized treatment plans. For instance, a study on 1914 women revealed cfDNA testing significantly reduces false positives for trisomies 21 and 18 compared to standard screening, with a 100% success rate in detecting aneuploidies and higher predictive values. Furthermore, simplified processes have increased the adoption of genetic testing across various healthcare settings, driving the genetic testing market demand.

INCREASING AWARENESS AND DEMAND FOR PERSONALIZED MEDICINE

Increasing awareness and demand for personalized medicine are playing a significant role in shaping the genetic testing market outlook. Personalized medicine, which relies on genetic information to tailor treatments, is driving the demand for genetic tests. This demand is particularly evident in sectors such as oncology and reproductive health, where genetic testing guides therapy decisions and assesses genetic disorder risks in offspring. For example, according to a study, a survey with a 36% response rate showed that 83% of the 312 respondents had minimal inquiries about direct-to-consumer genetic testing, 14% dealt with result interpretation, and over 50% supported the role of genetic counsellors and clinical settings for genetic testing, with 70% open to considering it for patients with privacy, anonymity, or access concerns. Additionally, the growing interest in understanding genetic predispositions to health conditions further bolsters the market growth.

RISE IN GENETIC DISORDERS AND CHRONIC DISEASES

The rise in genetic disorders and chronic diseases globally is further escalating the genetic testing market statistics. Genetic testing plays a vital role in the early detection, diagnosis, and management of various conditions like sickle cell anemia, cystic fibrosis, and Huntington's disease. Moreover, with the increasing incidence of chronic diseases, including cancer, cardiovascular diseases, and diabetes, there is a heightened need for testing to identify genetic mutations predisposing individuals to these conditions. The World Health Organization (WHO) reports that non-communicable diseases (NCDs), such as cancer, cardiovascular diseases, and diabetes, are responsible for 73% of global deaths annually. Genetic testing can help identify individuals at risk for these conditions. Early detection through testing improves patient outcomes, further propels the market. The genetic testing market is substantial, with a considerable growth in the number of genetic testing per year in the US and other developed countries. Genetic testing in pregnancy is also becoming increasingly prevalent, providing valuable insights into fetal health and genetic conditions.

GENETIC TESTING INDUSTRY SEGMENTATION:

ANALYSIS BY TYPE :

  • Predictive and Presymptomatic Testing
  • Carrier Testing
  • Prenatal and Newborn Testing
  • Diagnostic Testing
  • Pharmacogenomic Testing
  • Others

Diagnostic testing is employed to reveal or confirm specific inherited disease in symptomatic people. This sector is on the rise due to its contribution to a precise diagnosis, which is necessary for appropriate treatment and control of a plethora of genetic conditions. The fact of its broad fields of using from rare genetical diseases till common conditions brings attention to this issue in medical sector. Accurate diagnosis through diagnostic testing is critical for determining the most effective treatment strategies. Many conditions require specific therapies that depend on precise identification of the underlying issue. For instance, in infectious diseases, diagnostic tests such as cultures or polymerase chain reaction (PCR) tests can identify the causative pathogen, enabling the prescription of targeted antibiotics or antivirals. An investigation that appeared in the Journal of Molecular Diagnostics revealed that the percentage of medical professionals who had integrated genetic diagnostic testing for hereditary cancers definitely had grown from 19.8% in 2014 to 38.4% in 2018.

ANALYSIS BY TECHNOLOGY :

  • Cytogenetic Testing and Chromosome Analysis
  • Biochemical Testing
  • Molecular Testing
    • DNA Sequencing
    • Others

Molecular testing (DNA sequencing and others) leads the market with 45.2% of market share in 2025. Molecular testing portion cover PCR, NGS, and other filtered DNA related analysis terms. It is very practical as it can be applied for many sections, from detecting genetic changes that give rise to diseases, to exploring cancer genetics for the reason of targeted treatments, and to unearthing genetic predispositions for different conditions. The unique capability of molecular testing associated with the precision it offers has established the field of genetic diagnostics, individualized medicine, and research as a key area in molecular science, giving it a leading position in this field. A 2021 study evaluated various COVID-19 molecular tests, revealing a high sensitivity rate of 95.9% for minimizing false negatives, and a specificity rate of 97.2% to reduce false positives.

ANALYSIS BY APPLICATION :

  • Cancer Diagnosis
  • Genetic Disease Diagnosis
  • Cardiovascular Disease Diagnosis

Genetic disease diagnosis leads the market with 40.5% of market share in 2025. Genetic testing is currently utilized to diagnose a large number of diseases that are affected by both single-gene and multiple-gene factors. Genetic disease diagnosis is essential for the early detection of diseases and prompt intervention that finally aid in the condition's management. This is driven by its rear-rooted importance in the field of medicine which is represented in the accurate diagnoses of the genetic diseases not only for treatment but also for family planning. Between 2012 and 2022, the US led in the expansion of genetic tests, primarily for clinical diagnosis, highlighting the need for mandatory reporting and international collaboration for a comprehensive understanding of global genetic testing. Using genetic analysis for cancer diagnosis implies finding out genetic mutations or alterations which cause cancer to develop. This portion is very vital for early tumor detection, diagnosis and controlling different categories of cancer. Moreover, the genetic diagnosis of cardiovascular diseases involves locating these genetic variants to establish an increased risk for such heart-related defects as congenital heart defects, various cardiomyopathies, and arrhythmias.

REGIONAL ANALYSIS:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of 45.6%. North America is propelled by the top-notch healthcare infrastructure, high amount of money being spent on the healthcare sector and also the presence of top companies and research institutions. The region is driven by strong private investments, in the field of personalized medicine, large investments by governments on gene research and favorable policy decisions from the national government. Besides, genetic disorders as well as chronic diseases, with an increasing number of patients and an informed population willing to access testing services, enhance propel this company's leading position in the market. Moreover, companies are making genetic testing highly accessible to the general public, allowing people to purchase test kits online and conduct the process at home. The insights offered by these tests ranging from ancestry information to health risk assessments are generating widespread interest. This segment has particularly benefited from effective marketing strategies, increased awareness, and the growing demand for self-empowerment in health-related decisions. In 2024, Avalon GloboCare Corp., a leading organization in cell-based technology, precision diagnostics, and cellular therapy announced that Laboratory Services MSO, LLC ("LSM") introduced a direct to consumer (D2C) and non-invasive DNA testing kit for potential predisposition to opioid addiction. These kits are available in the US for effortless at home sample collection.

GENETIC TESTING REGIONAL TAKEAWAYS:

UNITED STATES GENETIC TESTING MARKET ANALYSIS

The United States accounts for 82.00% of the market share in North America. The US genetic testing market is driven by a combination of several factors. One of the key drivers is the rising prevalence of infectious diseases such as tuberculosis, HIV, and influenza, which increases the demand for effective detection and treatment solutions. The well-established healthcare infrastructure and government funding for research further support this demand, creating a favorable environment for market expansion. Additionally, the decision by UnitedHealthcare, the largest insurer in the U.S., to cover genetic tests for over 27 Million individuals since October 2019 is expected to prompt other insurers to follow suit, enhancing market accessibility. These favorable reimbursement trends help reduce the time spent finding optimal treatments, lower the costs of ineffective drugs, and contribute to the overall growth of the genetic testing market. Moreover, the economic burden of chronic diseases, such as cardiovascular conditions, which costs the U.S. healthcare system an estimated USD 320 Billion annually, according to the CDC, is driving a stronger emphasis on early diagnosis and preventive care, further accelerating the market's expansion.

ASIA PACIFIC GENETIC TESTING MARKET ANALYSIS

The Asia-Pacific genetic testing market is growing on account of a combination of factors including increasing awareness of the role of genetic testing in addressing public health challenges coupled with advancements in preventive care, as genetic testing helps identify risks for chronic diseases and hereditary disorders. With rapid urbanization and improved healthcare infrastructure, access to affordable genetic testing is expanding. Also, according to research by Bain, Asia-Pacific healthcare spending is expected to exceed 20% of global expenditure by 2030, with a notable 58% of Gen Z expressing willingness to invest in better health outcomes, underscoring the rising demand for personalized care. Public-private partnerships and culturally tailored awareness campaigns are also playing a key role in accelerating innovation, reducing stigma, and driving the acceptance of genetic health services in the region.

EUROPE GENETIC TESTING MARKET ANALYSIS

The adoption of genetic testing in Europe is being driven by the advancements in patient care, particularly through its incorporation with personalized medicine. Genetic insights are also driving the development of targeted therapies for conditions such as neurodegenerative and autoimmune diseases, improving precision treatment. In oncology, genetic testing is identifying mutations that facilitate personalized cancer treatments, which in turn leads to better prognoses. According to the European Union, approximately 5.9 Million cancer patients were discharged from EU hospitals in 2021, with Austria leading at 2,584 discharges per 100,000 inhabitants. Apart from this, the developments in genetic testing are also enhancing cancer care by tailoring interventions to individual genomic profiles, ensuring improved treatment and better outcomes. Additionally, the increasing accessibility of genetic counseling services is also supporting individuals with hereditary health concerns. These collaborative efforts among healthcare providers, governments, and research institutions are thus fostering standardized protocols, ensuring the quality and accuracy of genetic tests. These factors are collectively driving growth in the European genetic testing market.

LATIN AMERICA GENETIC TESTING MARKET ANALYSIS

Increased access to genetic testing in Latin America is significantly driving the genetic testing market in the region primarily by addressing disparities in healthcare delivery and outcomes. Also, the health expenditure in the region grew at an annual rate of 4.9% from 2010-2019, yet remaining below the OECD average, such data presents a lucrative market for genetic testing which has emerged as a cost-effective solution to enhance public health programs. By enabling early detection of genetic diseases, genetic testing also allows for proactive management, leading to improved survival rates and better health outcomes. Additionally, expanding genetic services in newborn screening programs is preventing lifelong complications from treatable conditions, which in turn is fostering greater health equity in the region. Thus, the growing awareness and improved affordability are encouraging wider adoption of genetic testing, empowering individuals to manage genetic health and enhancing overall health literacy.

MIDDLE EAST AND AFRICA GENETIC TESTING MARKET ANALYSIS

The expansion of the genetic testing market in the MENA region is relative to significantly improving the healthcare sector by adopting earlier diagnosis and treatment of inherited conditions. This technology plays a crucial role in population-specific research, identifying genetic variants that are more common in particular communities. Moreover, the high consanguinity rates ranging from 25-60%, and genetic disorders such as autosomal recessive syndromes, hemoglobinopathies, and Down syndrome being more prevalent in the region, the market is further propelling in the region. Also, prenatal testing, supported by genetic testing, is enhancing maternal and fetal health outcomes by reducing the occurrence of these genetic conditions.

COMPETITIVE LANDSCAPE:

Market's key players adopt different strategies to achieve fundamental objective of strengthening their market share. This include is investing heavily in research and development to innovation and evolution of genetic testing technologies, especially in the direction of next-generation sequencing (NGS) and CRISPR. They also engage in the establishment of partnerships and collaboration with other biotech companies, academic institutions, as well as healthcare providers to help them grow in their services portfolio and geographical reach. Besides this, manufacturers are making efforts to get the new devices approved by the regulator agencies to be in compliance with regulations and guarantee the patient safety. Additionally, direct-to-consumer (D2C) services have been developed with the aim of leveraging people's growing demand for personalized healthcare and genetic wellness. In 2024, LetsGetChecked announced the launch of myGeneticScreen, which is designed to provide patients with important and actionable insights into their predisposition for few hereditary conditions with end-to-end support, including personalized or customized health reports and access to genetic counselling.

The report provides a comprehensive analysis of the competitive landscape in the genetic testing market with detailed profiles of all major companies, including:

  • 23andme Inc.
  • Ambry Genetics Corporation (Konica Minolta Healthcare Americas Inc.)
  • Bio-RAD Laboratories Inc.
  • Cepheid (Danaher Corporation)
  • Eurofins Scientific
  • Illumina Inc.
  • Invitae Corporation
  • Luminex Corporation (DiaSorin)
  • Myriad Genetics Inc.
  • QIAGEN
  • Quest Diagnostics
  • Thermo Fisher Scientific

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What is genetic testing?

2. How big is the genetic testing market?

3. What is the expected growth rate of the global genetic testing market during 2026-2034?

4. What are the key factors driving the global genetic testing market?

5. What is the leading segment of the global genetic testing market based on type?

6. What is the leading segment of the global genetic testing market based on technology?

7. What is the leading segment of the global genetic testing market based on application?

8. What are the key regions in the global genetic testing market?

9. Who are the key players/companies in the global genetic testing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Genetic Testing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Predictive and Presymptomatic Testing
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Carrier Testing
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Prenatal and Newborn Testing
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Diagnostic Testing
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Pharmacogenomic Testing
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Cytogenetic Testing and Chromosome Analysis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biochemical Testing
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Molecular Testing
    • 7.3.1 Market Trends
    • 7.3.2 Key Segments
      • 7.3.2.1 DNA Sequencing
      • 7.3.2.1 Others
    • 7.3.3 Market Forecast

8 Market Breakup by Application

  • 8.1 Cancer Diagnosis
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Genetic Disease Diagnosis
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Cardiovascular Disease Diagnosis
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 23andme Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Ambry Genetics Corporation (Konica Minolta Healthcare Americas Inc.)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Bio-RAD Laboratories Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Cepheid (Danaher Corporation)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 SWOT Analysis
    • 14.3.5 Eurofins Scientific
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Illumina Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Invitae Corporation
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Luminex Corporation (DiaSorin)
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 SWOT Analysis
    • 14.3.9 Myriad Genetics Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 QIAGEN
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Quest Diagnostics
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Thermo Fisher Scientific
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Genetic Testing Market: Major Drivers and Challenges
  • Figure 2: Global: Genetic Testing Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Genetic Testing Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Genetic Testing Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Genetic Testing Market: Breakup by Technology (in %), 2025
  • Figure 6: Global: Genetic Testing Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Genetic Testing Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Genetic Testing (Predictive and Presymptomatic Testing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Genetic Testing (Predictive and Presymptomatic Testing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Genetic Testing (Carrier Testing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Genetic Testing (Carrier Testing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Genetic Testing (Prenatal and Newborn Testing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Genetic Testing (Prenatal and Newborn Testing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Genetic Testing (Diagnostic Testing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Genetic Testing (Diagnostic Testing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Genetic Testing (Pharmacogenomic Testing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Genetic Testing (Pharmacogenomic Testing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Genetic Testing (Other Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Genetic Testing (Other Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Genetic Testing (Cytogenetic Testing and Chromosome Analysis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Genetic Testing (Cytogenetic Testing and Chromosome Analysis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Genetic Testing (Biochemical Testing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Genetic Testing (Biochemical Testing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Genetic Testing (Molecular Testing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Genetic Testing (Molecular Testing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Genetic Testing (Cancer Diagnosis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Genetic Testing (Cancer Diagnosis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Genetic Testing (Genetic Disease Diagnosis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Genetic Testing (Genetic Disease Diagnosis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Genetic Testing (Cardiovascular Disease Diagnosis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Genetic Testing (Cardiovascular Disease Diagnosis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Genetic Testing (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Genetic Testing (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: North America: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: North America: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: United States: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: United States: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Canada: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Canada: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Asia-Pacific: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Asia-Pacific: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: China: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: China: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Japan: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Japan: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: India: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: India: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: South Korea: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: South Korea: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Australia: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Australia: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Indonesia: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Indonesia: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Others: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Others: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Europe: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Europe: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Germany: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Germany: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: France: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: France: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: United Kingdom: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: United Kingdom: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Italy: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Italy: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Spain: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Spain: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Russia: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Russia: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Others: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Others: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Latin America: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Latin America: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Brazil: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Brazil: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Mexico: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Mexico: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Others: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Others: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Middle East and Africa: Genetic Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Middle East and Africa: Genetic Testing Market: Breakup by Country (in %), 2025
  • Figure 82: Middle East and Africa: Genetic Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Global: Genetic Testing Industry: SWOT Analysis
  • Figure 84: Global: Genetic Testing Industry: Value Chain Analysis
  • Figure 85: Global: Genetic Testing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Genetic Testing Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Genetic Testing Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Genetic Testing Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 4: Global: Genetic Testing Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Genetic Testing Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Genetic Testing Market: Competitive Structure
  • Table 7: Global: Genetic Testing Market: Key Players